Nuclear factor e2-related factor 2 Dependent Overexpression of Sulfiredoxin and Peroxiredoxin III in Human Lung Cancer |
Kim, Young-Sun
(Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine)
Lee, Hye-Lim (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Lee, Ki-Bum (Department of Anatomical Pathology, Ajou University School of Medicine) Park, Joo-Hun (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Chung, Wou-Young (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Lee, Keu-Sung (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Sheen, Seung-Soo (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Park, Kwang-Joo (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) Hwang, Sung-Chul (Department of Pulmonary and Critical Care Medicine, Ajou University School of Medicine) |
1 | Rhee SG. Cell signaling: H2O2, a necessary evil for cell signaling. Science 2006;312:1882-1883. DOI ScienceOn |
2 | Chowdhury I, Mo Y, Gao L, Kazi A, Fisher AB, Feinstein SI. Oxidant stress stimulates expression of the human peroxiredoxin 6 gene by a transcriptional mechanism involving an antioxidant response element. Free Radic Biol Med 2009;46:146-153. DOI ScienceOn |
3 | Kang SW, Chae HZ, Seo MS, Kim K, Baines IC, Rhee SG. Mammalian peroxiredoxin isoforms can reduce hydrogen peroxide generated in response to growth factors and tumor necrosis factor-alpha. J Biol Chem 1998;273:6297-6302. DOI ScienceOn |
4 | Kang SW, Rhee SG, Chang TS, Jeong W, Choi MH. 2-Cys peroxiredoxin function in intracellular signal transduction: therapeutic implications. Trends Mol Med 2005;11:571-578. DOI ScienceOn |
5 | Chang TS, Jeong W, Woo HA, Lee SM, Park S, Rhee SG. Characterization of mammalian sulfiredoxin and its reactivation of hyperoxidized peroxiredoxin through reduction of cysteine sulfinic acid in the active site to cysteine. J Biol Chem 2004;279:50994-51001. DOI ScienceOn |
6 | Soriano FX, Baxter P, Murray LM, Sporn MB, Gillingwater TH, Hardingham GE. Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin. Mol Cells 2009;27:279-282. DOI ScienceOn |
7 | Woo HA, Jeong W, Chang TS, et al. Reduction of cysteine sulfinic acid by sulfiredoxin is specific to 2-cys peroxiredoxins. J Biol Chem 2005;280:3125-3128. DOI |
8 | Hubner RH, Schwartz JD, De Bishnu P, et al. Coordinate control of expression of Nrf2-modulated genes in the human small airway epithelium is highly responsive to cigarette smoking. Mol Med 2009;15:203-219. DOI ScienceOn |
9 | Rahman I. Antioxidant therapeutic advances in COPD. Ther Adv Respir Dis 2008;2:351-374. DOI ScienceOn |
10 | Singh A, Ling G, Suhasini AN, et al. Nrf2-dependent sulfiredoxin-1 expression protects against cigarette smoke-induced oxidative stress in lungs. Free Radic Biol Med 2009;46:376-386. DOI ScienceOn |
11 | Shibata T, Kokubu A, Gotoh M, et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008;135:1358-1368. DOI ScienceOn |
12 | Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008;58:262-270. DOI ScienceOn |
13 | Lei K, Townsend DM, Tew KD. Protein cysteine sulfinic acid reductase (sulfiredoxin) as a regulator of cell proliferation and drug response. Oncogene 2008;27:4877-4887. DOI ScienceOn |
14 | Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int Suppl 2007;(106):S3-S8. |
15 | Kwak MK, Wakabayashi N, Greenlaw JL, Yamamoto M, Kensler TW. Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol 2003;23:8786-8794. DOI ScienceOn |
16 | Cho HY, Jedlicka AE, Reddy SP, et al. Role of NRF2 in protection against hyperoxic lung injury in mice. Am J Respir Cell Mol Biol 2002;26:175-182. DOI ScienceOn |
17 | Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007;47:89-116. DOI ScienceOn |
18 | Cho HY, Reddy SP, Kleeberger SR. Nrf2 defends the lung from oxidative stress. Antioxid Redox Signal 2006;8:76-87. DOI ScienceOn |
19 | Colburn NH, Kensler TW. Targeting transcription factors for cancer prevention: the case of Nrf2. Cancer Prev Res (Phila) 2008;1:153-155. DOI ScienceOn |
20 | Kwak MK, Itoh K, Yamamoto M, Sutter TR, Kensler TW. Role of transcription factor Nrf2 in the induction of hepatic phase 2 and antioxidative enzymes in vivo by the cancer chemoprotective agent, 3H-1, 2-dimethiole-3-thione. Mol Med 2001;7:135-145. |
21 | Stacy DR, Ely K, Massion PP, et al. Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck 2006;28:813-818. DOI ScienceOn |
22 | Kwak MK, Itoh K, Yamamoto M, Kensler TW. Enhanced expression of the transcription factor Nrf2 by cancer chemopreventive agents: role of antioxidant response element-like sequences in the nrf2 promoter. Mol Cell Biol 2002;22:2883-2892. DOI ScienceOn |
23 | Osburn WO, Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008;659:31-39. DOI ScienceOn |
24 | Park JJ, Chang HW, Jeong EJ, et al. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2009;73:1196-1202. DOI ScienceOn |
25 | Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology 2006;11:269-275. DOI ScienceOn |
26 | Bae SH, Woo HA, Sung SH, et al. Induction of sulfiredoxin via an Nrf2-dependent pathway and hyperoxidation of peroxiredoxin III in the lungs of mice exposed to hyperoxia. Antioxid Redox Signal 2009;11:937-948. DOI ScienceOn |
27 | Findlay VJ, Tapiero H, Townsend DM. Sulfiredoxin: a potential therapeutic agent? Biomed Pharmacother 2005;59:374-379. DOI ScienceOn |
28 | Jeong W, Park SJ, Chang TS, Lee DY, Rhee SG. Molecular mechanism of the reduction of cysteine sulfinic acid of peroxiredoxin to cysteine by mammalian sulfiredoxin. J Biol Chem 2006;281:14400-14407. DOI ScienceOn |
29 | Noh YH, Baek JY, Jeong W, Rhee SG, Chang TS. Sulfiredoxin translocation into mitochondria plays a crucial role in reducing hyperoxidized peroxiredoxin III. J Biol Chem 2009;284:8470-8477. DOI |